The U.K. small aneurysm trial: Design, methods and progress  by The UK Small Aneurysm Trial Participants, 
Eur J Vasc Endovasc Surg 9, 4248 (1995) 
The U.K. Small Aneurysm Trial: Design, Methods and Progress 
The UK Small Aneurysm Trial Participants 
Objectives: To study the outcome of surgery versus ultrasound surveillance for small aortic aneurysms. 
Design: Multicentre, random allocation, open trial. 
Setting: University and general hospitals across the UK. 
Materials, Patients aged 60-76 years with small asymptomatic abdominal aortic aneurysms (4-5.5 cm in diameter). 
Chief Outcome Measures, The mortality rate, costs, usage of health service resources and quality of life of each treatment 
will be compared. 
Conclusions: From patients randomised to ultrasound surveillance, the natural history of small aneurysms will be 
determined. The design, methods and progress of this trial are reported here. 
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Introduction 
Background 
Abdominal aortic aneurysm is a common condition. 
There is evidence from Britain, America and Australia 
that the number of aortic aneurysms presenting, both 
electively and for rupture, is increasing in absolute 
terms. 1-3 Population screening studies indicate that 
the prevalence of abdominal aortic aneurysm in men 
over 65 years is about 5%. 4"5 This "epidemic" of 
aneurysms together with the aging population is 
likely to impose increasing burdens on health 
resources in Europe. 
Over the past decade surgical and anaesthetic 
techniques have improved rapidly, such that 30-day 
mortality rates of <5% are reported for elective 
aneurysm repair. 6, 7 However, overall national mortal- 
ity rates for elective aneurysm surgery may be higher, s 
Nevertheless, in contrast with the improvement of 
mortality associated with elective surgery, mortality 
rates associated with grafting for ruptured aneurysms 
remain high ( - 40%). 9 Despite the increasing numbers 
of elective aneurysm repairs, the number of patients 
admitted with ruptured aortic aneurysm also con- 
tinues to increase. 1 The dilemma for the vascular 
surgeon, is whether to operate arly and electively on 
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All vascular surgeons consider elective surgery when 
an abdominal aortic aneurysm reaches 6 cm in 
diameter. Some surgeons have advocated elective 
surgery for a patient of any age with an aneurysm of 
4 cm or more in diameter. ~2 For most there is a grey 
area of uncertainty concerning the best management 
of aneurysms between 4 and 6 cm in diameter. After 
vigorous discussion at the Vascular Surgical Society of 
Great Britain and Ireland a group of surgeons agreed 
upon their grey area of uncertainty: asymptomatic 
aneurysms of 4.0-5.5 cm in diameter in fit patients 
aged 60-76 years. These surgeons agreed to participate 
in a random allocation trial of early elective surgery or 
ultrasound surveillance in such patients. 
Clearly, the establishment of a multicentre trial 
provided the opportunity to answer other important 
questions, aside from whether all cause mortality was 
reduced by early elective surgery of 4.0-5.5 cm 
diameter aneurysms. The trial will provide an oppor- 
tunity to investigate the growth and rupture rates of 
small aneurysms, factors associated with accelerated 
small asymptomatic abdominal aortic aneurysms orto 
observe the aneurysm for increase in size. The risk of 
rupture is very low in small aneurysms but increases 
with increasing diameter. 1°'11 
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Fig. 1. Main organisational structure of the trial. 
aneurysmal growth, costings and patients' quality of 
life for the two treatments and how 24-hour and 
30-day mortality rates for elective aneurysm surgery 
across Britain, vary according to age, sex, aneurysm 
size and concomitant ischaemic heart disease. 
Organisational Structure 
The Steering Committee has responsibility for fund- 
ing, running and reporting the trial. 13 Consecutive 
patients are recruited from all participating surgeons 
(Fig. 1). The surgeon sees patients together with the 
local trial co-ordinator (five co-ordinators cover the 
five regions in Britain). Each trial co-ordinator isbased 
in one of five hospitals, where they are supervised by 
a surgeon who functions as Regional Trial Director (in 
Bath, Edinburgh, Leicester, London and Manchester). 
The trial co-ordinators collect and forward the patient 
data to the trial statistician in London. The Steering 
Committee arranges regular meetings for trial co- 
ordinators and participating surgeons and reviews 
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Fig. 2. Outline of trial design. 
recruitment at regular intervals. The Steering Commit- 
tee appointed a Monitoring Committee, which ensures 
the proper running of the trial and also functions as a 
Stopping Committee. The Monitoring Committee 
receives regular reports from the trial statistician, 
particularly with respect o deaths. All others, includ- 
ing the Steering Committee and trial participants, 
have no access to information on deaths in the trial. 
The outline design for the trial is given in Fig. 2. 
The recruitment of patients derives from referrals to 
the participating vascular surgeons. These referrals 
normally come from general practitioners, other hos- 
pital departments and from hospital or community 
based screening programmes. The trial co-ordinators 
have been trained together to use portable ultrasound 
equipment to optimise standardisation f aortic diam- 
eter assessment. 14 We have chosen the Aloka SSD-500 
equipped with a 3.5 mHz probe for these investiga- 
tions. Random cross-checking between operators can 
be performed by measurement of hard copy image. 
The trial co-ordinators also meet at regular intervals to 
standardise their readings of blood pressure and lung 
function. 
Apart from the initial patient recruitment form, 
which is completed by the surgeon, the remainder of 
the paperwork is completed by the trial co-ordinator. 
All patients aged between 60-76 years with an 
asymptomatic aneurysm are included. All patients 
with asymptomatic aneurysms of < 4 cm are followed 
up by the trial co-ordinators at either 6 or 12 monthly 
intervals to monitor the aneurysm for growth. All 
patients with an aneurysm diameter between 4.0-5.5 
cm who are fit for surgery are considered for entry 
into the trial. Those unwilling or considered unfit for 
surgery enter the study for observation of aneurysm 
growth rates. 
The fate of those patients with asymptomatic 
aneurysms >5.5 cm is also being documented. 
Patients who are unfit for surgery, where possible are 
also followed to monitor aneurysm growth and from 
those fit for surgery 30-day operative mortality rate is 
determined. 
Those patients who are considered fit for elective 
surgery and agree to enter the trial are randomised 
using a telephone computer link line. For patients who 
are randomised to elective surgery, the operation 
should be scheduled within the following 3 months. 
For patients who are randomised to ultrasound 
surveillance, there are regular follow-up 
appointments. 
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Recruitment, Randomisation and Sample Size 
Recruitment 
Recruitment of patients is through the consultant 
trialists. When agreeing to the study it is emphasised 
that all patients with a non-ruptured infra-renal aortic 
aneurysm who are between the ages of 60 and 76 years 
should be registerex~. At the first visit following 
registration the patient with an aneurysm 4.0-5.5 cm 
in diameter is seen by the co-ordinator together with 
the surgeon to discuss entry to the trial. Patients who 
are not suitable for entry into the trial are offered 
follow-up by the trial co-ordinator. 
Randomisation 
If a patient is considered suitable for entry into the 
trial the co-ordinator contacts the randomisation 
computer established in collaboration with British 
Telecom plc, which is held at the Central Co-ordinat- 
ing Office. This method of randomisation is unique in 
that the computer esponds to the telephone call and 
understands the responses to a series of questions 
used to confirm the patient's, suitability for the trial. 
The computer ecords details of the patient, hospital 
and consultant surgeon. This information can then be 
accessed by the Central Co-ordinating Office. The 
treatment allocated is immediately available to the co- 
ordinator, surgeon and patient. This service is availa- 
ble 24 hours a day together with information on 
treatment allocation of previous patients. 
Sample size 
The required sample size was estimated to be 1000 
patients (500 in each arm of the trial). This estimate 
was dependent on the predicted mortality in the 
surgical and surveillance groups. However, in keeping 
with most trials, the incidence of the outcome measure 
was not known precisely and was based on the best 
available evidence when the trial was designed. We 
assumed a 30-day mortality of 2% associated with 
elective surgery and a 2% annual mortality in the 
observation group due to aneurysm rupture or sub- 
sequent surgery, if the aneurysm enlarges rapidly or 
symptoms developed. Mortality due to other causes in 
a typical population with small abdominal aortic 
aneurysm was estimated to be about 6% per annum. 
With recruitment of 1000 patients, the trial will, over a 
5-year period of follow-up, have a 
predictability of 80% to detect a 7% difference in 
mortality at p < 0.05. The 95% confidence limits of 
mortality in either group will be + 3%. The sample 
size will also be adequate to detect differences in 
quality of life and other outcome measures and, in the 
surveillance arm of the trial will detect differences in 
the prognostic factors related to aneurysm growth. 
Eligibility and Exclusion Criteria 
Eligibility criteria and exclusions 
All patients between the ages of 60 and 76 with an 
unruptured aneurysm are entered into the aneurysm 
study. Randomisation i to the trial requires that the 
maximum antero-posterior diameter should not be 
less than 4.0 cm and not exceeding 5.5 cm as measured 
by the trial co-ordinator. 
Specific exclusions for this trial are: (i) patients 
who refuse to be randomised; (ii) patients who are 
unfit for surgery; (iii) patients with symptoms refer- 
rable to the aneurysm; (iv) patients who are unable to 
give informed consent; (v) patients who are unable to 
attend for regular follow-up. 
Informed consent 
A patient who meets the entry criteria is informed 
fully about he trial and provided with an information 
sheet, a copy of which is sent to the patient's family 
practitioner. Patients may, if they ask, be given a 
period of time, usually around one month, to consider 
the options before being asked for consent to randomi- 
sation. Where there is doubt about fitness for surger~ 
further assessment and discussion with the surgeon 
and anaesthetist ensues before seeking consent. 
Fitness for surgery 
There are no specific investigations prescribed for 
surgeons to decide on suitability for surgery. The 
surgeons follow their normal routine for preoperative 
assessment. Some patients require other treatments, 
e.g. for hypertension, before being considered fit for 
surgery. 
The Steering Committee did not seek to define 
criteria for fitness for surger~ since it was considered 
unlikely that universal agreement among surgeons 
and anaesthetists was achievable and the wish was to 
reflect practice as it pertained nationwide. 
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Treatment Groups, Visits and Procedures 
At randomisation the patients are assigned to either 
early elective surgery or regular ultrasound 
surveillance. 
performs quality of life assessments, records changes 
in cardiovascular details (including recent cardiovas- 
cular events) and  details of use of health service 
resources by the patient. The only further follow-up 
required by the trial is data on mortality which are 
obtained from the NHS central registry. 
Entry to the trial - -  baseline data 
Included in the initial interview are questions on 
previous medical history, particularly with respect o 
history of respiratory disease, diabetes and hyper- 
tension. The Rose angina and claudication ques- 
tionnaires are administered, together with a ques- 
tionnaire on smoking history. ~s Family history of 
aortic aneurysm and family history of early predis- 
position to atherosclerosis are assessed. All drugs 
currently taken are recorded and categorised accord- 
ing to their groupings in the British National For- 
mulary. 16 Cardiovascular and respiratory drugs are 
coded individually. 
Measurements are taken of height, weight, ankle- 
brachial systolic pressure indices using hand held 
Doppler, systolic and diastolic blood pressure and 
respiratory functions of vital capacity and forced 
expiratory volume using a hand held spirometer. 
Widest anteroposterior infra-renal aortic diameter is 
taken as previously described. ~4 A non-fasting blood 
sample is taken for analysis of total cholesterol HDL- 
cholesterol triglycerides, fibrinogen, creatinine, hae- 
matocrit and white cell count. HDL-cholesterol and 
fibrinogen are measured in a central laboratory at 
Charing Cross, other variables are measured locally. 
Patients who are suitable for the trial undergo a chest 
X-ray from which the cardiothoracic ratio is deter- 
mined. An electrocardiograph is taken which is coded 
accorded to the Minnesota Classification. 
Surgery 
After a patient has been randomised to early elective 
surgery the surgeon trialist should try to schedule the 
operation within the next three months. Surgical 
details including type of graft, surgeon and anaes- 
thetist rank, findings at operation, need for reopera- 
tion and 30-day mortality are recorded by the trial co- 
ordinator. 
After discharge patients are seen at 1 month by 
the surgeon trialist, and at 6 months and i year by the 
trial co-ordinator. At the 6-month and 1-year visits 
patients are seen by the trial co-ordinator who 
Ultrasound surveillance 
Patients who are assigned to the surveillance arm of 
the trial are seen by the trial co-ordinator on a regular 
basis as described previouslj6 usually at the surgeon's 
outpatient clinic. Patients (aneurysm diameter 4.0-5.0 
cm) who are randomised to ultrasound surveillance 
are reviewed at 6-monthly intervals. However, if the 
aneurysm diameter is between 5.0 and 5.5 cm the 
interval between visits is shortened to 3 months. 
Should the aneurysm grow to beyond 5.5 cm, rapidly 
increase in diameter (> 1 cm/year), or the patient 
develop symptoms, surgery may be considered. At 
this time the surgeon is informed of the change in 
status and makes a decision on the patient's uitability 
for surgery. 
The follow-up procedures are similar to those for 
the group assigned to surgery except hat the aneu- 
rysm diameter and patient's blood pressure are also 
measured. Information is also collected about changes 
in medication and smoking habit. These surveillance 
visits continue until either the patient dies, the trial 
ends or surgery is considered and effected. Surgery is 
considered only when the aneurysm reaches 5.5 cm, 
grows rapidl)~ or becomes symptomatic. At the 
12-month follow-up visit a further blood sample is 
obtained for the analysis of plasma cotinine. 
Outcome Measures 
Mortality 
The principal end point for this trial is mortality. 
Operative mortality is assessed at 30 days and all 
causes of death recorded. All patients are given a card 
which gives information on the trial and which is 
carried at all times. This includes a number to ring in 
the event of a serious event or death. Other mortality 
data are obtained from hospital records and family 
practitioner notes. All patients entered into the trial 
are "flagged" with the NHS Central Registry which 
provides a copy of the death certificate when a patient 
dies. 
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Quality of life 
The Medical Outcomes Study short form general 
health survey is being used throughout his trial. 18 
This provides information on a number of self 
assessed scales for physical and social functioning, 
mental health, health perceptions and pain, with 
scores from 0 to 100. These assessments are made 
when the initial questionnaire is completed and at all 
follow-up visits made by the nurse co-ordinator. 
Growth rates 
Information on growth rates is derived from serial 
measurements of the aortic diameter in patients 
randomised to ultrasound surveillance. There is addi- 
tional information on growth rates provided from 
patients outside the trial: those with 3-3.9 cm aneu- 
rysms and those with larger aneurysms (> 5.5 cm) 
who are not fit or will not consent to elective 
surgery. 
Cost effectiveness 
In order to determine the cost effectiveness of surgery 
compared to observation, the health service costs of 
both treatment options will be determined. The costs 
of admission for elective aneurysm repair are being 
determined for 50 patients in a specialist vascular unit 
in a teaching hospital and in a district general surgical 
unit. This costing includes a detailed assessment of the 
costs of such resources as staffing, investigations, 
drugs, and overheads consumed uring the pre- and 
post-operative periods. In addition, the costs of the 
operation are being determined for 15 operations. All 
operations are recorded and coded according to a 
standard classification. 19The costs of an ultrasound 
examination are also being estimated, based on staff 
time, use of equipment, consumables and overheads. 
For each of the costings, sensitivity analyses will 
be carried out so that estimates may be adjusted 
according to differing use of major resources in 
different centres. For example, the effects on costs of 
different average lengths of postoperative stay can be 
estimated. The extent to which the use of major 
resources might vary between centres will be deter- 
mined by means of a questionnaire s nt to all surgeons 
participating in the trial. 
In addition to these costing exercises, the nurse 
co-ordinators are collecting data on the use of health 
service resources by each patient. At 6-monthly 
intervals, the number and type of health service 
contacts in relation to the aneurysm (e.g. in-patient 
admission, out-patient attendance and family practi- 
tioner consultation) are being obtained from each 
patient in the trial. This information is obtained using 
a short questionnaire administered by the co-ordinator 
at the 6-monthly ultrasound examination for the 
observation group or at the 6-month and 1-year 
postoperative follow-up on the surgical group. 
The cost estimates outlined above will be com- 
bined to generate a total programme cost for the 
surgical and observation arms of the trial. The relative 
cost of these alternatives will be examined in terms of 
their association with survival rates and the corre- 
sponding number of life years gained. 
Results and Statistical Analyses 
Interim analysis - -  stopping rules 
Operative (30 day) mortality. Operative (30 day) 
mortality is expected to be of the order of 2%. The 
monitoring committee considers that a 5% (30d) 
mortality is unacceptable. Surgical mortality will be 
analysed cumulatively after each 100 patients rando- 
mised to surgery have had aortic aneurysm surgery. 
Confidence intervals have been calculated that give 
the lower bound for stopping the trial at 5%. This 
gives the cumulative number of deaths for stopping 
the trial at 11 for the first 100 patients, 18 for 200, 25 for 
300, 30 for 400, and 36 for 500 patients operated. 
Interim comparisons ofgroups. It is anticipated that four 
interim analyses and one final analysis will take place 
throughout the trial. The O'Brien Fleming boundaries 
will be used as the basis for stopping the trial. 2° The 
overall probabilities for a treatment benefit will be set 
at p = 0.05, with an adverse ffect set at p = 0.10. Since 
350 deaths are expected in this trial the interim 
analyses will be after 70, 140, 210, 280 and finally after 
350 deaths. 
Final analysis. As given above the final analysis will be 
expected to occur after 350 patients have died in this 
trial. The survival analysis will be performed using 
the Cox proportional hazards model with time to 
death as the principal end point for the trial, as The 
survival model will be adjusted for potential con- 
founding variables which are expected to influence 
mortality. These will include age, sex, history of 
ischaemic heart disease, peripheral arterial disease, 
hypertension and chronic obstructive airways disease. 
Proportionality will be assured using the methods of 
Kalbfleisch and Prentice. 2a 
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Conclusion 
The first patients were assessed for suitability to enter 
the trial in August  1991. Since that t ime more than =~ • ~ 20 
2,469 patients have been registered and of these 2,176 
have had a decision made on their treatment (Fig. % 
3). 
The half way  point for entry into the trial, the = 10 
randomisat ion of 500 patients was achieved in Octo- 
ber 1993. The randomised patient populat ion com- 
prised 85% men and 15% women,  with a mean age of 
69.1 years (S.D. = 4.5). The distr ibution of aneurysm 0 
diameters is shown in Fig. 4. 4.0-4.2 4.3-4.5 
The management  of small abdomina l  aortic aneu- 
rysms is like many other important  issues of surgical 
practice, most  appropr iate ly investigated by  means of 
a mult icentre random allocation trial. In order to 
determine whether  early elective surgery or ultra- 
sound surveil lance is the better management  modal i ty  
for small abdomina l  aortic aneurysms,  within a 
relatively short t ime frame, we have chosen a trial 
structure which focuses on high qual ity data through 
the employment  of dedicated trial co-ordinators. The 
U.K. Small Aneurysm Trial is scheduled to close in 
July 1996 after randomisat ion of 1,000 patients. The 
f ramework  of the trial has been designed so that 
several other important  issues can be addressed, 
These other issues include the costs of treatment, the 
qual ity of life for each treatment and the identif ication 
of factors associated with the rapid growth of small 
Key 
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[ ]  3.0-3.9 cm 
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[ ]  other I 
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Fig. 3. Distribution of 2,176 decisions made on patients entered into 
the U.K. Aneurysm Trial. Of the total, 21% met the inclusion criteria 
for the trial and were randomised. 
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Fig. 4. Distribution of antero-posterior aneurysm diameter in 
patients randomised in the U.K. Small Aneurysm Trial. 
aneurysms. The part icipating surgeons are listed in 
the appendix:  the success of this trial will be attrib- 
uted, in large part, to their enthusiasm. With barriers 
d isappear ing in Europe we hope that other important  
issues in vascular surgery can be addressed by  similar 
large trials recruit ing patients f rom several countries. 
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